material, sales promotion costs, trade margins, quality assurance cost, landed cost of imports etc.

As a part of price monitoring activity, NPPA regularly examines the movement in prices of non-Scheduled formulations. The monthly reports of ORG IMS and the information furnished by individual manufacturers are utilized for the purpose of monitoring prices of non-Scheduled formulations. Wherever a price increase beyond 10% per annum w.e.f. 1.4.2007 (prior to 1.4.2007 it was 20% per annum) is noticed, the manufacturer is asked to bring down the price voluntarily failing which, subject to prescribed conditions action is initiated under paragraph 10(b) of the DPCO, 1995 for fixing the price of the formulation in public interest. This is an ongoing process.

Based on monitoring of prices of non-Scheduled formulations, NPPA has fixed prices in case of 27 formulation packs under para 10(b) and companies have reduced price voluntarily in case of 64 formulation packs. Thus in all, prices of 91 packs of non-scheduled drugs have got reduced as a result of the intervention of NPPA. There is no separate mechanism in DPCO, 1995 to control the prices of medicines being manufactured in excise free Zones.

Sale of anti-asthma drugs at higher prices

1716. SHRI AMAR SINGH: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether it is a fact that large number of companies producing anti-asthma products containing Salbutamol and Leavo Salbutamol are not following the ceiling prices and are selling their products at much higher prices;

(b) if so, whether Government has conducted any inquiry in this regard, and if so, the details thereof; and

(c) the action being taken against those companies?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI SRIKANT JENA): (a) Yes, Sir.

(b) and (c) National Pharmaceutical Pricing authority (NPPA) has informed that certain companies were found selling Salbutamol and Leavo Salbutamol based medicines over and above the ceiling price fixed by NPPA. NPPA has issued notices to all such companies. Names of the companies where demand of overcharging have been quantified and their present status of recovery are given in Statement (*See* below). As number of cases related to Salbutamol bulk drug and related formulations are lying in various Courts and are sub-judice, the recovery of the amount depends on the outcome of these Court Cases.

Statement

Names of the Companies where demands of over choosing have been quantified and their present status of Recovery

Sl. No.	Name of the Company (M/s)	Name of Formulation	Estimated Overcharged amount and interest (Rs. In lakhs)	Recovered amount (Rs. in lakhs)	Present Status
1	2	3	4	5	6
1.	Cipla Ltd.	Salbutamol	6438.99		Matter is subjudice
2.	SGS Pharmaceuticals Pvt. Ltd.	Salbutamol tabs	0.17	0.12	Under process
3.	Manish Pharma Lab.	Salbutamol Sulphate	0.23	0.23	Closed as amount recovered
4.	Kopran Ltd.	Salbutamol based formulations	698.9		Matter is subjudice
5.	US Vitamins Ltd./ Neo Pharma	Salbutamol based formulations	29.04		Under process
6.	Biddle Sawyer Ltd.	Salbutamol based formulations	27.47		Under process
7.	Cipla Ltd.	Salbutamol based formulations	45064.61		Matter is subjudice
8.	Khandelwal Labs	Salbutamol based formulations	2.74	2.74	Closed as amount recovered
9.	Esskay Pharmaceuticals Ltd.	Dexares tabs and Salbutamol sulphate tabs	14.75		Referred to Official liquidator
10.	Karnani Pharma (P) Ltd.	Salbaxine Tabs	0.08	0.08	Closed as amount recovered
11.	Eros Pharma	Salbid 4 mg and 8 mg	1.62	1.62	Closed as amount recovered